Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Endocrine therapy in ovarian cancer: where do we stand?

Paleari L, DeCensi A.

Curr Opin Obstet Gynecol. 2018 Feb;30(1):17-22. doi: 10.1097/GCO.0000000000000423.

PMID:
29176513
2.

A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene.

Noonan S, Pasa A, Fontana V, Caviglia S, Bonanni B, Costa A, Smith SG, Peccatori F, DeCensi A.

Cancer Prev Res (Phila). 2018 Jan;11(1):38-43. doi: 10.1158/1940-6207.CAPR-17-0162. Epub 2017 Oct 23.

PMID:
29061559
3.

64CuCl2 PET/CT in prostate cancer relapse.

Piccardo A, Paparo F, Puntoni M, Righi S, Bottoni G, Bacigalupo L, Zanardi S, DeCensi A, Ferrarazzo G, Gambaro M, Grillo Ruggieri F, Campodonico F, Tomasello L, Timossi L, Sola S, Lopci E, Cabria M.

J Nucl Med. 2017 Sep 8. pii: jnumed.117.195628. doi: 10.2967/jnumed.117.195628. [Epub ahead of print]

PMID:
28887398
4.

Repurposing metformin for the prevention of cancer and cancer recurrence.

Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG.

Diabetologia. 2017 Sep;60(9):1639-1647. doi: 10.1007/s00125-017-4372-6. Epub 2017 Aug 3. Review.

PMID:
28776080
5.

Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.

Paleari L, Gandini S, Provinciali N, Puntoni M, Colombo N, DeCensi A.

Gynecol Oncol. 2017 Sep;146(3):504-513. doi: 10.1016/j.ygyno.2017.06.036. Epub 2017 Jul 10. Review.

6.

Worry and risk perception of breast cancer in a prevention trial of low dose tamoxifen in midlife postmenopausal hormone users.

Rondanina G, Puntoni M, Guerrieri-Gonzaga A, Marra D, Bonanni B, DeCensi A.

Breast. 2017 Aug;34:108-114. doi: 10.1016/j.breast.2017.05.008. Epub 2017 May 29.

PMID:
28570956
7.

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.

Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G.

Ann Oncol. 2017 Feb 1;28(2):321-328. doi: 10.1093/annonc/mdw623.

PMID:
28426105
8.

A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2017 Jun;10(6):363-370. doi: 10.1158/1940-6207.CAPR-16-0298. Epub 2017 Apr 11.

PMID:
28400479
9.

Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.

Lazzeroni M, Dunn BK, Pruneri G, Jereczek-Fossa BA, Orecchia R, Bonanni B, DeCensi A.

Cancer Treat Rev. 2017 Apr;55:1-9. doi: 10.1016/j.ctrv.2017.01.010. Epub 2017 Feb 11. Review.

PMID:
28262606
10.

Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes.

Smith SG, Foy R, McGowan JA, Kobayashi LC, DeCensi A, Brown K, Side L, Cuzick J.

Br J Gen Pract. 2017 Jun;67(659):e414-e427. doi: 10.3399/bjgp17X689377. Epub 2017 Feb 13.

11.

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer.

Campora S, Campazzi E, Zanardi S, Puntoni M, Piccininno M, Piccardo A, Shoushtari Zadeh Naseri M, Defferrari C, Provinciali N, Petrera M, Marra D, Biscaldi E, Antonucci GC, Ricci D, Clavarezza M, Gennari A, Gozza A, D'Amico M, Mori M, DeCensi A.

Transl Oncol. 2016 Dec;9(6):600-605. doi: 10.1016/j.tranon.2016.08.001. Review.

12.

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.

Oza AM, Selle F, Davidenko I, Korach J, Mendiola C, Pautier P, Chmielowska E, Bamias A, DeCensi A, Zvirbule Z, González-Martín A, Hegg R, Joly F, Zamagni C, Gadducci A, Martin N, Robb S, Colombo N.

Int J Gynecol Cancer. 2017 Jan;27(1):50-58. doi: 10.1097/IGC.0000000000000836.

13.

Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.

Provinciali N, Suen C, Dunn BK, DeCensi A.

Expert Rev Clin Pharmacol. 2016 Sep 12:1-10. [Epub ahead of print]

PMID:
27583816
14.

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.

Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.

Breast Cancer Res Treat. 2016 Aug;159(1):97-108. doi: 10.1007/s10549-016-3932-7. Epub 2016 Aug 2.

PMID:
27484880
15.

Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.

Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A.

Int J Cancer. 2016 Nov 1;139(9):2127-34. doi: 10.1002/ijc.30254. Epub 2016 Jul 19.

16.

Cancer Prevention and Interception: A New Era for Chemopreventive Approaches.

Albini A, DeCensi A, Cavalli F, Costa A.

Clin Cancer Res. 2016 Sep 1;22(17):4322-7. doi: 10.1158/1078-0432.CCR-16-0695. Epub 2016 May 24.

17.

Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.

Clavarezza M, Puntoni M, Gennari A, Paleari L, Provinciali N, D'Amico M, DeCensi A.

Clin Cancer Res. 2016 Sep 15;22(18):4594-603. doi: 10.1158/1078-0432.CCR-15-1881. Epub 2016 May 2.

18.

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.

Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, Bruno S, Curotto A, DeCensi A.

Cancer Prev Res (Phila). 2016 Jun;9(6):437-44. doi: 10.1158/1940-6207.CAPR-15-0345. Epub 2016 Apr 4.

19.

Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).

Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F.

Ann Oncol. 2016 Jun;27(6):1006-13. doi: 10.1093/annonc/mdw147. Epub 2016 Mar 30.

PMID:
27029706
20.

Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.

Capitanio S, Bongioanni F, Piccardo A, Campus C, Gonella R, Tixi L, Naseri M, Pennone M, Altrinetti V, Buschiazzo A, Bossert I, Fiz F, Bruno A, DeCensi A, Sambuceti G, Morbelli S.

World J Radiol. 2016 Feb 28;8(2):200-9. doi: 10.4329/wjr.v8.i2.200.

21.

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E.

Semin Oncol. 2016 Feb;43(1):123-133. doi: 10.1053/j.seminoncol.2015.09.009. Epub 2015 Sep 8. Review.

22.

Alternate dosing schedules for cancer chemopreventive agents.

Lazzeroni M, DeCensi A.

Semin Oncol. 2016 Feb;43(1):116-122. doi: 10.1053/j.seminoncol.2015.09.014. Epub 2015 Sep 7. Review.

PMID:
26970130
23.

A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.

Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, Toesca A, Caldarella P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 May;9(5):349-56. doi: 10.1158/1940-6207.CAPR-15-0311. Epub 2016 Feb 29.

24.

Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.

Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, Gandini S.

Int J Cancer. 2016 Jul 1;139(1):212-9. doi: 10.1002/ijc.30062. Epub 2016 Mar 12.

25.

PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.

Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A.

Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26. doi: 10.1016/j.clon.2015.11.008. Epub 2015 Dec 17. Review.

PMID:
26712086
26.

Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.

DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J.

Ecancermedicalscience. 2015 Nov 24;9:595. doi: 10.3332/ecancer.2015.595. eCollection 2015. Review.

27.

A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 Jan;9(1):89-95. doi: 10.1158/1940-6207.CAPR-15-0123. Epub 2015 Nov 2.

28.

Metformin: risk-benefit profile with a focus on cancer.

Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi A.

Expert Opin Drug Saf. 2015 Oct;14(10):1573-85. doi: 10.1517/14740338.2015.1084289. Epub 2015 Sep 11. Review.

PMID:
26359221
29.

Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G.

Cancer Prev Res (Phila). 2015 Oct;8(10):888-94. doi: 10.1158/1940-6207.CAPR-15-0048. Epub 2015 Aug 14.

30.

Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.

Bruno S, Ledda B, Tenca C, Ravera S, Orengo AM, Mazzarello AN, Pesenti E, Casciaro S, Racchi O, Ghiotto F, Marini C, Sambuceti G, DeCensi A, Fais F.

Oncotarget. 2015 Sep 8;6(26):22624-40.

31.

18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.

Piccardo A, Puntoni M, Morbelli S, Massollo M, Bongioanni F, Paparo F, Altrinetti V, Gonella R, Gennari A, Iacozzi M, Sambuceti G, DeCensi A.

Nuklearmedizin. 2015;54(4):163-72. doi: 10.3413/Nukmed-0727-15-02. Epub 2015 Jul 13.

PMID:
26165806
32.

Multimodality fusion imaging in abdominal and pelvic malignancies: current applications and future perspectives.

Paparo F, Piccardo A, Bacigalupo L, Piccazzo R, Rollandi L, Galletto Pregliasco A, Filauro M, DeCensi A, Rollandi GA.

Abdom Imaging. 2015 Oct;40(7):2723-37. doi: 10.1007/s00261-015-0435-7.

PMID:
25952574
33.

Long-term effects of inhaled budesonide on screening-detected lung nodules.

Veronesi G, Lazzeroni M, Szabo E, Brown PH, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Grimaldi MC, Spaggiari L, Bonanni B.

Ann Oncol. 2015 May;26(5):1025-30. doi: 10.1093/annonc/mdv064. Epub 2015 Feb 11.

34.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.

Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25.

35.

An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.

D'Amico M, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, Gozza A, Zanardi S, Defferrari C, Provinciali N, Campazzi E, Campora S, Paleari L, Marra D, Petrera M, DeCensi A.

Expert Opin Drug Saf. 2014 Nov;13(11):1437-42. doi: 10.1517/14740338.2014.960388. Epub 2014 Sep 16.

PMID:
25224760
36.

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E.

Cancer Prev Res (Phila). 2014 Sep;7(9):867-85. doi: 10.1158/1940-6207.CAPR-13-0424. Epub 2014 Jul 1. Review.

37.

The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis.

Smith T, Elwood P, Keating C, Rothwell P, Detering E, Freedman A, Langley R, Logan R, Phillips C, DeCensi A.

Ecancermedicalscience. 2014 Jan 24;8:388. doi: 10.3332/ecancer.2014.388. eCollection 2014.

38.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.

Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S.

Breast Cancer Res Treat. 2014 Apr;144(2):321-9. doi: 10.1007/s10549-014-2849-2. Epub 2014 Feb 1.

39.

Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.

Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A.

Ann Oncol. 2014 Mar;25(3):618-23. doi: 10.1093/annonc/mdt528. Epub 2013 Dec 18.

40.

Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.

Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Macis D, Puccio A, Sandri MT, Gulisano M, Formelli F, Decensi A.

Breast Cancer Res Treat. 2013 Dec;142(3):569-78. doi: 10.1007/s10549-013-2768-7. Epub 2013 Nov 17.

PMID:
24241787
41.

The effect of metformin on apoptosis in a breast cancer presurgical trial.

Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B.

Br J Cancer. 2013 Nov 26;109(11):2792-7. doi: 10.1038/bjc.2013.657. Epub 2013 Oct 24.

42.

Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.

Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, Antonucci G, Amadori D, Bruzzi P.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1862-7. doi: 10.1158/1055-9965.EPI-13-0595. Epub 2013 Aug 14.

43.

Breast cancer prevention by antihormones and other drugs: where do we stand?

Lazzeroni M, DeCensi A.

Hematol Oncol Clin North Am. 2013 Aug;27(4):657-72, vii. doi: 10.1016/j.hoc.2013.05.009. Review.

PMID:
23915737
44.

A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.

DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, Sideri M, Cassano E, Belloni C, Muraca M, Segnan N, Masullo P, Costa A, Monti N, Vella A, Bisanti L, D'Aiuto G, Veronesi U; Italian HOT Study Group.

Ann Oncol. 2013 Nov;24(11):2753-60. doi: 10.1093/annonc/mdt244. Epub 2013 Jul 17.

PMID:
23864098
45.

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.

Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM.

J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8. Review. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.

PMID:
23835710
46.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B.

Breast Cancer Res. 2013 Jun 20;15(3):R47. doi: 10.1186/bcr3439.

47.

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; SERM Chemoprevention of Breast Cancer Overview Group.

Lancet. 2013 May 25;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3. Epub 2013 Apr 30. Review.

48.

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.

Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Del Castillo A, Bassi F, Pagani G, DeCensi A, Viale G, Bonanni B, Pruneri G.

Br J Cancer. 2013 Apr 30;108(8):1593-601. doi: 10.1038/bjc.2013.147. Epub 2013 Apr 11.

49.

Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer.

Dunn BK, Cazzaniga M, DeCensi A.

Breast. 2013 Jun;22(3):225-37. doi: 10.1016/j.breast.2013.02.015. Epub 2013 Mar 25. Review.

PMID:
23535509
50.

Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.

Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, Cazzaniga M, Bollani G, Mora S, Montefrancesco C, Pruneri G, Viale G, Intra M, Galimberti V, Goldhirsch A, Bagnardi V, Bonanni B, DeCensi A.

Ann Oncol. 2013 Jul;24(7):1859-66. doi: 10.1093/annonc/mdt113. Epub 2013 Mar 26.

PMID:
23532115

Supplemental Content

Loading ...
Support Center